Evan Bloch

List of Publications by Year
in descending order

150 papers	5,324 citations	136950 32 h-index	114465 63 g-index
172 all docs	172 docs citations	172 times ranked	8620 citing authors

#	Article	IF	Citations
1	Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational caseâ€“control study. Journal of Clinical Pathology, 2022, 75, 564-571.	2.0	15
2	International survey of strategies to mitigate t<scp>ransfusionâ€transmitted</scp>Trypanosoma cruzi in n<scp>onâ€endemic</scp> countries, 2016â€“2018. Vox Sanguinis, 2022, 117, 58-63.	1.5	6
3	Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in Blood Donor Populations. Journal of Infectious Diseases, 2022, 225, 1-4.	4.0	8
4	Pharmacokinetics of high-titer antiâ€“SARS-CoV-2 human convalescent plasma in high-risk children. JCI Insight, 2022, 7, .	5.0	12
5	COVIDâ€19 and the impact on blood availability and transfusion practices in lowâ€and middleâ€income countries. Transfusion, 2022, 62, 336-345.	1.6	7
6	Experience with <scp>COVID</scp>â€19 convalescent plasma provides vital guidance to future pandemics. Transfusion, 2022, 62, 681-684.	1.6	6
7	Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. Journal of Clinical Microbiology, 2022, 60, jcm0239021.	3.9	5
8	Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy. Journal of Clinical Apheresis, 2022, 37, 253-262.	1.3	7
9	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight, 2022, 7, .	5.0	12
10	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. BMC Immunology, 2022, 23, 7.	2.2	6
11	Status of hospital-based blood transfusion services in low-income and middle-income countries: a cross-sectional international survey. BMJ Open, 2022, 12, e055017.	1.9	10
12	Early Outpatient Treatment for Covid-19 with Convalescent Plasma. New England Journal of Medicine, 2022, 386, 1700-1711.	27.0	194
13	International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the <scp>COVID</scp>â€19 pandemic. Vox Sanguinis, 2022, 117, 822-830.	1.5	17
14	The feasibility of multiple units of convalescent plasma in mechanically ventilated patients with COVID-19: A pilot study. Transfusion and Apheresis Science, 2022, , 103423.	1.0	0
15	Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike. ELife, 2022, 11, .	6.0	26
16	Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 ⁺ T-Cell Epitopes Identified in COVID-19 Convalescent Individuals. MBio, 2022, 13, e0361721.	4.1	67
17	How do I implement an outpatient program for the administration of convalescent plasma for <scp>COVID</scp> â€19?. Transfusion, 2022, , .	1.6	13
18	The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial. Trials, 2022, 23, 257.	1.6	7

#	Article	IF	Citations
19	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. Transplantation Direct, 2022, 8, e1268.	1.6	14
20	Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Advances, 2022, 6, 3678-3683.	5.2	42
21	Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates. Haemophilia, 2022, , .	2.1	3
22	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. Transfusion Medicine Reviews, 2022, 36, 125-132.	2.0	8
23	Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals. PLoS ONE, 2022, 17, e0264298.	2.5	0
24	Clinical use of Convalescent Plasma in the COVIDâ€19 pandemic: a transfusionâ€focussed gap analysis with recommendations for future research priorities. Vox Sanguinis, 2021, 116, 88-98.	1.5	30
25	Guidance for the procurement of COVIDâ€19 convalescent plasma: differences between highâ€and lowâ€middleâ€income countries. Vox Sanguinis, 2021, 116, 18-35.	1.5	48
26	Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers. Journal of Clinical Microbiology, 2021, 59, .	3.9	170
27	Promoting access to COVID-19 convalescent plasma in low- and middle-income countries. Transfusion and Apheresis Science, 2021, 60, 102957.	1.0	28
28	Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point-of-Care Testing. Journal of Clinical Microbiology, 2021, 59, .	3.9	46
29	ABO blood group and SARSâ€CoVâ€2 antibody response in a convalescent donor population. Vox Sanguinis, 2021, 116, 766-773.	1.5	22
30	Filariasis and transfusionâ€associated risk: a literature review. Vox Sanguinis, 2021, 116, 741-754.	1.5	4
31	ABO blood group and COVIDâ€19: a review on behalf of the ISBT COVIDâ€19 Working Group. Vox Sanguinis, 2021, 116, 849-861.	1.5	108
32	Slower response to treatment of ironâ€deficiency anaemia in pregnant women infected with HIV: a prospective cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1674-1681.	2.3	0
33	Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. Cell Reports, 2021, 34, 108863.	6.4	92
34	CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants. Open Forum Infectious Diseases, 2021, 8, ofab143.	0.9	83
35	Lessons learned in the collection of convalescent plasma during the COVIDâ€19 pandemic. Vox Sanguinis, 2021, 116, 872-879.	1.5	8
36	<scp>COVID</scp>â€19 convalescent plasma: Interim recommendations from the <scp>AABB</scp>. Transfusion, 2021, 61, 1313-1323.	1.6	40

#	Article	IF	Citations
37	SARS-CoV-2â€“specific CD8+ T cell responses in convalescent COVID-19 individuals. Journal of Clinical Investigation, 2021, 131, .	8.2	213
38	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. Journal of Clinical Investigation, 2021, 131, .	8.2	58
39	Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. MBio, 2021, 12, .	4.1	57
40	Transplant of SARS-CoV-2â€“infected Living Donor Liver: Case Report. Transplantation Direct, 2021, 7, e721.	1.6	16
41	Low rates of transfusionâ€transmitted infection screening in chronically transfused adults with sickle cell disease. Transfusion, 2021, 61, 2421-2429.	1.6	1
42	Risk of transfusionâ€transmitted Babesia microti in Canada. Transfusion, 2021, 61, 2958-2968.	1.6	6
43	Blood transfusions in gunshotâ€woundâ€related emergency department visits and hospitalizations in the United States. Transfusion, 2021, 61, 2277-2289.	1.6	3
44	Blood transfusion trends in the United States: national inpatient sample, 2015 to 2018. Blood Advances, 2021, 5, 4179-4184.	5.2	9
45	Causes of death after biannual azithromycin treatment: A community-level randomized clinical trial. PLoS ONE, 2021, 16, e0250197.	2.5	0
46	A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels. Journal of Clinical Microbiology, 2021, 59, e0118621.	3.9	6
47	Preventing Transfusion-Transmitted Babesiosis. Pathogens, 2021, 10, 1176.	2.8	17
48	Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient. Transfusion and Apheresis Science, 2021, 60, 103180.	1.0	0
49	Bacterial contamination of blood products in Africa. Transfusion, 2021, 61, 767-780.	1.6	7
50	Pathology Residency Program Special Expertise Tracks Meet the Needs of an Evolving Field. Academic Pathology, 2021, 8, 23742895211037034.	1.1	4
51	Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer. Journal of Infectious Diseases, 2021, 223, 740-742.	4.0	5
52	Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma. Open Forum Infectious Diseases, 2021, 8, ofaa574.	0.9	41
53	InÂvivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential. Cell Reports, 2021, 37, 109838.	6.4	8
54	Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers. Journal of Clinical Virology, 2021, 145, 104997.	3.1	28

#	Article	IF	Citations
55	Blood Product (Donor) Noninfectious and Infectious Testing and Modification. Clinics in Laboratory Medicine, 2021, 41, 579-598.	1.4	0
56	Powassan virus: What is the risk to the blood supply?. Transfusion, 2021, 61, 3286-3288.	1.6	2
57	Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Medicine, 2021, 18, e1003872.	8.4	43
58	Morbidity in a Longitudinal Cohort of Children Residing in Villages Randomized to Biannual Treatment With Azithromycin Versus Placebo. Clinical Infectious Diseases, 2020, 70, 574-580.	5.8	3
59	A riskâ€based decisionâ€making framework for blood safety: what's the case for Zika?. ISBT Science Series, 2020, 15, 31-39.	1.1	1
60	Antenatal blood transfusion in South Africa: indications and practice in a highâ€HIVâ€prevalence setting. Transfusion, 2020, 60, 479-487.	1.6	2
61	Secondary bacterial culture of platelets to mitigate transfusionâ€associated sepsis: A 3â€year analysis at a large academic institution. Transfusion, 2020, 60, 2021-2028.	1.6	7
62	Blood Transfusion Safety in Low-Resourced Countries: Aspiring to a Higher Standard. Annals of Internal Medicine, 2020, 173, 482-483.	3.9	11
63	Convalescent plasma to treat COVID-19. Blood, 2020, 136, 654-655.	1.4	31
64	Implementation outcomes of policy and programme innovations to prevent obstetric haemorrhage in low- and middle-income countries: a systematic review. Health Policy and Planning, 2020, 35, 1208-1227.	2.7	2
65	Comparative changes of preâ€operative autologous transfusions and periâ€operative cell salvage in the United States. Transfusion, 2020, 60, 2260-2271.	1.6	3
66	SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. Journal of Infectious Diseases, 2020, 222, 1974-1984.	4.0	96
67	Cryoprecipitate Utilization Patterns Observed With a Required Prospective Approval Process vs Electronic Dosing Guidance. American Journal of Clinical Pathology, 2020, 154, 362-368.	0.7	3
68	Individualâ€and hospitalâ€level correlates of red blood cell, platelet, and plasma transfusions among hospitalized children and neonates: a nationally representative study in the United States. Transfusion, 2020, 60, 1700-1712.	1.6	17
69	Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program. Transfusion, 2020, 60, 1243-1252.	1.6	8
70	Isohemagglutinin titering performed on an automated solidâ€phase and hemagglutininâ€based analyzer is comparable to results obtained by manual gel testing. Transfusion, 2020, 60, 628-636.	1.6	14
71	Financial analysis of largeâ€volume delayed sampling to reduce bacterial contamination of platelets. Transfusion, 2020, 60, 997-1002.	1.6	15
72	Malaria parasitemia among blood donors in Uganda. Transfusion, 2020, 60, 955-964.	1.6	11

#	Article	IF	Citations
73	Perioperative Transfusions and Venous Thromboembolism. Pediatrics, 2020, 145, .	2.1	16
74	How did we rapidly implement a convalescent plasma program?. Transfusion, 2020, 60, 1348-1355.	1.6	40
75	Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation, 2020, 130, 2757-2765.	8.2	649
76	Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. Journal of Clinical Investigation, 2020, 130, 6141-6150.	8.2	375
77	Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors. PLoS ONE, 2020, 15, e0243950.	2.5	12
78	Impact of Biannual Azithromycin on Anemia in Preschool Children in Kilosa District, Tanzania: A Cluster-Randomized Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1311-1314.	1.4	2
79	Biannual Treatment of Preschool Children with Single Dose Azithromycin to Reduce Mortality: Impact on Azithromycin Resistance in the MORDOR Trial in Tanzania. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1301-1307.	1.4	5
80	Mortality and Associated Comorbidities Among Patients Hospitalized for Deep Vein Thrombosis and Pulmonary Embolism in the United States: Results from a Nationally Representative Database. Blood, 2020, 136, 39-40.	1.4	3
81	Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors. , 2020, 15, e0243950.		0
82	Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors. , 2020, 15, e0243950.		0
83	Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors. , 2020, 15, e0243950.		0
84	Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors. , 2020, 15, e0243950.		0
85	The Babesia observational antibody (BAOBAB) study: A cross-sectional evaluation of Babesia in two communities in Kilosa district, Tanzania. PLoS Neglected Tropical Diseases, 2019, 13, e0007632.	3.0	6
86	Human Seroprevalence of Tick-BorneAnaplasma phagocytophilum,Borrelia burgdorferi, andRickettsiaSpecies in Northern California. Vector-Borne and Zoonotic Diseases, 2019, 19, 871-878.	1.5	9
87	Persistence of Babesia microti Infection in Humans. Pathogens, 2019, 8, 102.	2.8	61
88	The impact on malaria of biannual treatment with azithromycin in children age less than 5Âyears: a prospective study. Malaria Journal, 2019, 18, 284.	2.3	3
89	Sociodemographic and behavioral characteristics associated with blood donation in the United States: a populationâ€based study. Transfusion, 2019, 59, 2899-2907.	1.6	37
90	Oneâ€unit compared to twoâ€unit platelet transfusions for adult oncology outpatients. Vox Sanguinis, 2019, 114, 517-522.	1.5	7

#	Article	IF	Citations
91	Prevention of transfusion-transmitted infections. Blood, 2019, 133, 1854-1864.	1.4	164
92	Hemostatic properties of coldâ€stored whole blood leukoreduced using a plateletâ€sparing versus a nonâ€“plateletâ€sparing filter. Transfusion, 2019, 59, 1809-1817.	1.6	28
93	Association of blood donation with iron deficiency among adolescent and adult females in the United States: a nationally representative study. Transfusion, 2019, 59, 1723-1733.	1.6	25
94	Capturing the passenger leukocyte. Transfusion, 2019, 59, 3291-3292.	1.6	0
95	International survey on the impact of parasitic infections: frequency of transmission and current mitigation strategies. Vox Sanguinis, 2019, 114, 17-27.	1.5	15
96	Blood transfusion safety in subâ€Saharan Africa: A literature review of changes and challenges in the 21st century. Transfusion, 2019, 59, 412-427.	1.6	72
97	Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions. Transfusion, 2019, 59, 1291-1299.	1.6	21
98	A Cross-Sectional Study of the Availability of Azithromycin in Local Pharmacies and Associated Antibiotic Resistance in Communities in Kilosa District, Tanzania. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1105-1109.	1.4	4
99	Therapeutic plasma exchange for hyperviscosity syndrome secondary to high rheumatoid factor. Transfusion and Apheresis Science, 2018, 57, 225-227.	1.0	6
100	Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions. Transfusion, 2018, 58, 1647-1653.	1.6	34
101	A pilot serosurvey of Babesia microti in Chinese blood donors. Vox Sanguinis, 2018, 113, 345-349.	1.5	11
102	Funding blood safety in the 21st century. Transfusion, 2018, 58, 105-112.	1.6	14
103	Pathogen reduction and blood transfusion safety in Africa: strengths, limitations and challenges of implementation in lowâ€resource settings. Vox Sanguinis, 2018, 113, 3-12.	1.5	37
104	The epidemiology of bacterial cultureâ€“positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016. Transfusion, 2018, 58, 1933-1939.	1.6	19
105	Genomic Epidemiology Reconstructs the Introduction and Spread of Zika Virus in Central America and Mexico. Cell Host and Microbe, 2018, 23, 855-864.e7.	11.0	82
106	Risk factors for peripartum blood transfusion in South Africa: a caseâ€control study. Transfusion, 2018, 58, 2149-2156.	1.6	13
107	Revisiting Blood Safety Practices Given Emerging Data about Zika Virus. New England Journal of Medicine, 2018, 378, 1837-1841.	27.0	28
108	Babesia microti and Malaria Infection in Africa: A Pilot Serosurvey in Kilosa District, Tanzania. American Journal of Tropical Medicine and Hygiene, 2018, 99, 51-56.	1.4	15

#	Article	IF	Citations
109	Zika Virus: Knowledge Assessment of Residents and Health-Care Providers in RoatÃ¡n, Honduras, following an Outbreak. American Journal of Tropical Medicine and Hygiene, 2018, 99, 211-215.	1.4	6
110	A rare, potentially lifeâ€threatening presentation of passenger lymphocyte syndrome. Transfusion, 2017, 57, 1262-1266.	1.6	11
111	Teenage Blood Donors: Are We Asking Too Little and Taking Too Much?. Pediatrics, 2017, 139, .	2.1	17
112	Patient Blood Management. , 2017, , 105-133.		1
113	Residual risk of bacterial contamination: what are the options?. Transfusion, 2017, 57, 2289-2292.	1.6	13
114	Blood Product Utilization Among Trauma and Nontrauma Massive Transfusion Protocols at an Urban Academic Medical Center. Anesthesia and Analgesia, 2017, 125, 967-974.	2.2	13
115	How do we manage blood donors and recipients after a positive Zika screening result?. Transfusion, 2017, 57, 2077-2083.	1.6	9
116	Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease. Transfusion, 2017, 57, 2267-2276.	1.6	21
117	Zika Virus and the Blood Supply: What Do We Know?. Transfusion Medicine Reviews, 2017, 31, 1-10.	2.0	42
118	Use of Blood Donor Screening to Monitor Prevalence of HIV and Hepatitis B and C Viruses, South Africa. Emerging Infectious Diseases, 2017, 23, 1560-1563.	4.3	17
119	Real-Time Evolution of Zika Virus Disease Outbreak, RoatÃ¡n, Honduras. Emerging Infectious Diseases, 2017, 23, 1360-1363.	4.3	17
120	Antibiotic Resistance in Young Children in Kilosa District, Tanzania 4 Years after Mass Distribution of Azithromycin for Trachoma Control. American Journal of Tropical Medicine and Hygiene, 2017, 97, 815-818.	1.4	18
121	A cross-sectional study of peripartum blood transfusion in the Eastern Cape, South Africa. South African Medical Journal, 2016, 106, 1103.	0.6	4
122	A Literature Review of Zika Virus. Emerging Infectious Diseases, 2016, 22, 1185-1192.	4.3	418
123	Babesia screening: the importance of reporting and calibration in costâ€effectiveness models. Transfusion, 2016, 56, 774-775.	1.6	2
124	A prospective evaluation of chronic Babesia microti infection in seroreactive blood donors. Transfusion, 2016, 56, 1875-1882.	1.6	20
125	A retrospective analysis of falseâ€positive infectious screening results in blood donors. Transfusion, 2016, 56, 457-465.	1.6	16
126	Screening for transfusion transmissible infections using rapid diagnostic tests in Africa: a potential hazard to blood safety?. Vox Sanguinis, 2016, 110, 196-198.	1.5	18

#	Article	IF	Citations
127	Emerging Infections and Blood Safety in the 21st Century. Annals of Internal Medicine, 2016, 165, 57.	3.9	10
128	Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay. Transfusion, 2016, 56, 1866-1874.	1.6	31
129	The contribution of unsafe blood transfusion to human immunodeficiency virus incidence in subâ€Saharan Africa: reexamination of the 5% to 10% convention. Transfusion, 2016, 56, 3121-3132.	1.6	12
130	The impact of human immunodeficiency virus infection on obstetric hemorrhage and blood transfusion in South Africa. Transfusion, 2015, 55, 1675-1684.	1.6	13
131	Motivators and deterrents to blood donation among Black South Africans: a qualitative analysis of focus group data. Transfusion Medicine, 2015, 25, 249-258.	1.1	34
132	The Use of Rapid Diagnostic Tests for Transfusion Infectious Screening in Africa: A Literature Review. Transfusion Medicine Reviews, 2015, 29, 35-44.	2.0	49
133	A Cross-Sectional Pilot Study of Blood Utilization in 27 Hospitals in Northern California. American Journal of Clinical Pathology, 2014, 142, 498-505.	0.7	7
134	Determination of <scp>B</scp>abesia microti seroprevalence in blood donor populations using an investigational enzyme immunoassay. Transfusion, 2014, 54, 2237-2244.	1.6	37
135	Microchimerism in the transfused obstetric population. Vox Sanguinis, 2014, 107, 428-430.	1.5	3
136	A pilot external quality assurance study of transfusion screening for HIV, HCV and HBsAG in 12 African countries. Vox Sanguinis, 2014, 107, 333-342.	1.5	35
137	Costs, consequences, and costâ€effectiveness of strategies for <scp>B</scp>abesia microti donor screening of the <scp>US</scp> blood supply. Transfusion, 2014, 54, 2245-2257.	1.6	30
138	Transfusion-Associated Microchimerism: The Hybrid Within. Transfusion Medicine Reviews, 2013, 27, 10-20.	2.0	40
139	Development of a realâ€time polymerase chain reaction assay for sensitive detection and quantitation of <scp>Babesia microti</scp> infection. Transfusion, 2013, 53, 2299-2306.	1.6	41
140	Fatal Transplant-Associated West Nile Virus Encephalitis and Public Health Investigationâ€"California, 2010. Transplantation, 2013, 96, 463-468.	1.0	22
141	A GBS culture collected shortly after GBS prophylaxis may be inaccurate. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 736-738.	1.5	1
142	The third described case of transfusionâ€transmitted Babesia duncani. Transfusion, 2012, 52, 1517-1522.	1.6	71
143	Reasons for blood donation deferral in subâ€Saharan Africa: experience in Ivory Coast. Transfusion, 2012, 52, 1602-1606.	1.6	22
144	Blood Transfusion Safety in Africa: A Literature Review of Infectious Disease and Organizational Challenges. Transfusion Medicine Reviews, 2012, 26, 164-180.	2.0	136

#	Article	IF	Citations
145	A review of the use of blood and blood products in HIV-infected patients. Southern African Journal of HIV Medicine, 2012, 13, 87-104.	0.9	5
146	Male microchimerism in peripheral blood leukocytes from women with multiple sclerosis. Chimerism, 2011, 2, 6-10.	0.7	19
147	Male microchimerism in peripheral blood leukocytes from women with multiple sclerosis. Chimerism, 2011, 2, 6-10.	0.7	9
148	526: A GBS culture collected after antibiotic administration may be inaccurate. American Journal of Obstetrics and Gynecology, 2008, 199, S154.	1.3	0
149	Imaging of an Invasive Malignant Thymoma on PET Scan: CT and Histopathologic Correlation. Clinical Nuclear Medicine, 2006, 31, 614-616.	1.3	8
150	Implementation of national blood conservation recommendations at an adult sickle cell center. Transfusion, 0, , .	1.6	2